BioSpace News Archive

Sparrow Pharmaceuticals presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” at the 2022 Annual European Congress of Rheumatology.

Gilead Sciences, Inc. announced positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® versus physicians’ choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

Pfizer Inc. announced overall survival results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

Tumor DNA circulating in the bloodstream can help clinicians decide whether chemotherapy is right for their patients who have undergone surgery for stage II colon cancer, according to a breakthrough study published online in The New England Journal of Medicine and presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Everest Medicines announces that its licensing partner, Gilead Sciences, Inc., reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® versus physicians’ choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

Curis, Inc. announced the presentation of encouraging clinical data from both the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting currently taking place in Chicago and online until June 7, 2022.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, presented new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel in the treatment of multiple myeloma at the 2022 American Society of Clinical Oncology Annual Meeting.

Kite, a Gilead Company, announced findings from two pre-planned, subgroup analyses of the landmark ZUMA-7 trial of Yescarta®, which led to the U.S. Food and Drug Administration’s recent expanded approval of Yescarta as initial treatment in adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced EMA regulatory progress and tabelecleucel clinical outcomes.

Puma Biotechnology, Inc., a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology Annual Meeting.